{
    "clinical_study": {
        "@rank": "166566", 
        "arm_group": {
            "arm_group_label": "Survey"
        }, 
        "brief_summary": {
            "textblock": "This study is conducted in the United States of America (USA). The aim of the study is to\n      assess the minimal important difference (MID) of the TRIM-AGHD."
        }, 
        "brief_title": "Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Growth Hormone Disorder", 
            "Adult Growth Hormone Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism, Pituitary", 
                "Endocrine System Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to speak read and write English\n\n          -  GHD (Growth Hormone Deficiency) treatment na\u00efve which is defined as not being on a\n             prescription treatment for their GHD currently and for at least 6 months\n\n          -  Beginning a new prescription GHD treatment and expected to be on this treatment for\n             GHD for a minimum of 6 months\n\n          -  GHD of either one of the following criteria: a) Adult onset: subjects who have GHD,\n             either alone or associated with multiple hormone deficiencies (hypopituitarism), as a\n             result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or\n             traumatic brain injury (TBI), b) Childhood Onset: Subjects who were growth hormone\n             deficient during childhood as a result of congenital, genetic, acquired, or\n             idiopathic causes\n\n          -  Confirmed diagnosis of growth hormone deficiency (if a subject satisfies any one of\n             the three following criteria): a) For the insulin tolerance test (ITT) or glucagon\n             test both performed within the last five years: the validated cut-off for GHD in\n             adults is a peak GH response of below 3.0 ng/mL (3 microg/L), b) For growth hormone\n             releasing hormone (GHRH) +Arginine test performed within the last five years: for\n             those subjects with a body mass index (BMI) below 25 kg/m^2, a peak GH below 11 ng/mL\n             (microg /L); for BMI 25-30 kg/m^2, a peak GH below 8 ng/mL (8 microg/L); for BMI\n             above 30 kg/m^2, a peak GH below 4 ng/mL 341 (4 microg/L ), c) Three or more\n             pituitary hormone deficiencies at screening\n\n          -  Informed consent obtained before any study-related activities. (Study-related\n             activities are any procedure related to recording of data according to the protocol)\n\n        Exclusion Criteria:\n\n          -  Mental incapacity, unwillingness or language barriers precluding adequate\n             understanding or cooperation\n\n          -  Patients who have been on a prescription medication for treatment of GHD in past 6\n             months\n\n          -  Patients with a total Beck Depression Inventory II (BDI-II) score greater than 25\n\n          -  Females who are pregnant, breast-feeding or intend to become pregnant or are not\n             using adequate contraceptive methods (adequate contraceptive measures as required by\n             local law or practice)\n\n          -  Acute severe illness associated with weight loss in the last 6 months (defined as a\n             loss of more than 5.0% total body weight)\n\n          -  Active Cushings syndrome within the last 24 months\n\n          -  Subject with overt diabetes mellitus\n\n          -  Previous participation in this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "23 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients with a diagnosis of growth hormone deficiency (GHD), na\u00efve to treatment\n        currently and for at least 6 months prior, who are beginning a new prescription treatment\n        for their GHD. Patients will be selected by sites as per inclusion and exclusion criteria"
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005198", 
            "org_study_id": "NN8640-4123", 
            "secondary_id": "U1111-1146-1750"
        }, 
        "intervention": {
            "arm_group_label": "Survey", 
            "description": "Subject will only fill out a questionnaire when entering the non-interventional study", 
            "intervention_name": "No treatment given", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 4, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Princeton", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08540"
                }, 
                "name": "Novo Nordisk Clinical Trial Call Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Changes in CGI (Clinician Global Impression Scale)", 
                "safety_issue": "No", 
                "time_frame": "After the physician scheduled visits closest to week 8 and week 26 after initiation of treatment"
            }, 
            {
                "measure": "Changes in PGI (Patient Global Impression Scale)", 
                "safety_issue": "No", 
                "time_frame": "After the physician scheduled visits closest to week 8 and week 26 after initiation of treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005198"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}